DGKA and myocardial infarction: These data suggest that short-term, systemic delivery of a selective DGKα inhibitor reduces MQ infiltration, inflammation, and MMP activity during the acute phase and further mitigates adverse LV remodeling during the chronic phase in mouse MI.